A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
about
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitisPsychological interventions for treatment of inflammatory bowel diseaseShort chain fatty acids (butyrate) for induction of remission in ulcerative colitisRectal 5-aminosalicylic acid for induction of remission in ulcerative colitisTacrolimus (FK506) for induction of remission in refractory ulcerative colitisPsychological interventions for treatment of inflammatory bowel diseaseExaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel diseaseCurrent approaches for optimizing the benefit of biologic therapy in ulcerative colitisAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialEvaluation of inflammatory activity in Crohn's disease and ulcerative colitisClinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiologyRosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data.Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.Multi-matrix system mesalamine: to use or not to use.The diagnosis and treatment of Crohn's disease and ulcerative colitisProspective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patientsClinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)Limitations in assessment of mucosal healing in inflammatory bowel diseaseEffects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitisShort health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease.Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitisOphthalmologic manifestations in patients with inflammatory bowel disease.Poorly responsive ulcerative colitis in the hospitalGolimumab for the treatment of ulcerative colitis.In vivo analysis of mucosal lipids reveals histological disease activity in ulcerative colitis using endoscope-coupled Raman spectroscopyAberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis.The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis.European evidence-based Consensus on the management of ulcerative colitis: Current management.Relationship between methylation and colonic inflammation in inflammatory bowel disease.Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity indexSerum beta 2-microglobulin as a biomarker in inflammatory bowel diseaseThe possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease.Nutrient intake and bone mineral density by nutritional status in patients with inflammatory bowel disease.Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoidsCytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity.
P2860
Q24187044-B9FC1036-211B-4ACE-A93D-AF004526C21AQ24234176-A6379A26-7F69-4C5F-96D5-DE76BD3E342FQ24234780-DBD388DE-1D92-4501-9B41-0E4256B646F2Q24240567-F0B15463-0CA9-4C07-8A5C-75E5FEDDCD86Q24242681-C8EADE90-18C1-4D7D-BFBC-3C46CA53E227Q24243610-0B2254F5-B6C9-4066-B17F-CA63F7EBD767Q24653651-9A8913A0-970A-4943-9EF0-E8102E1C492AQ26745712-7B74011A-945B-49BE-A9B7-D251243EA89EQ26829488-8E12F8F5-985B-4EA0-A767-80F3DE2FE82CQ26996550-FD78E2C6-06AA-494D-8547-95478E033D6DQ28072104-7B8737FC-8E2E-4261-9226-14A3C207E5DCQ28534532-E981108C-D240-4B27-899F-0FB5A19C6718Q30440147-744793D0-D740-47EA-A4D7-161A91927845Q30643321-B4E160CA-E1FB-4E33-B3D2-5F8C0C0695B7Q31141014-234CF43C-2E78-4328-AB2D-1145CAABB57BQ33438982-A1F27317-124A-4B3F-A6E0-25A2A77226DEQ33476811-0380B3D6-4462-420A-9168-CB284374EA1EQ33497983-F057E2A8-BD52-4A44-AB46-323E46A2C48FQ33536129-9DE959B3-CF5F-426E-AE0D-7D77059A8244Q33557634-1B0357FE-75BD-4432-AC5D-1B689E04B43FQ33564957-79DBCAAF-ABD8-420C-85D9-5FAA33B4BC3BQ33606202-7B101D07-D0ED-4CBC-8544-85F5BF0BC8E8Q33696416-89966872-935D-42AF-8CBF-A917E0A98298Q33719997-6F9B875C-EE37-4625-8FD4-6B83FB143A2FQ33810986-E2B333F3-4B42-4F81-A591-DB8554A63AA0Q33819519-A39B73DC-FE7F-4C34-9833-C70C1DF9C426Q33831982-D86C3CEC-1684-47B7-B28C-82FAC2369AD6Q33852257-3FE28872-E8C0-4E6C-9467-3366C8B2243BQ33901644-E4CC7E88-911A-4DD3-AD36-05BF64B6CEA7Q33962421-A86967FB-5A51-4B12-9F87-061CDFC53803Q34011689-B186E19E-4207-4B00-97BB-AA5737739E2EQ34025054-633BB11A-C6D9-417F-A2B4-9FBB69426BB9Q34036817-95EDCA7F-12AA-424A-B28E-EB88AAEB9FB7Q34047972-70159131-FCFD-49DC-A9BF-8468AFA7D475Q34065540-9F377B34-6325-46C7-9A41-8677E53A0D10Q34067914-7771791C-D3CB-4621-B27F-8B4A3C80FFACQ34119277-5374712A-0A74-48F6-AE55-9E53DD9AB83BQ34219185-C356A7B5-C20C-44E8-AD02-0061339D3038Q34291196-5E76C8D0-958C-486C-B074-6E32FF8D001EQ34414068-2C7EA040-7729-42F9-B586-B79F5932621A
P2860
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A review of activity indices a ...... dults with ulcerative colitis.
@ast
A review of activity indices a ...... dults with ulcerative colitis.
@en
type
label
A review of activity indices a ...... dults with ulcerative colitis.
@ast
A review of activity indices a ...... dults with ulcerative colitis.
@en
prefLabel
A review of activity indices a ...... dults with ulcerative colitis.
@ast
A review of activity indices a ...... dults with ulcerative colitis.
@en
P2093
P50
P1433
P1476
A review of activity indices a ...... dults with ulcerative colitis.
@en
P2093
E Jan Irvine
Jurgen Schölmerich
Lloyd R Sutherland
Marc Lémann
Philippe Marteau
Stephen B Hanauer
P304
P356
10.1053/J.GASTRO.2006.12.038
P407
P577
2006-12-20T00:00:00Z